Imiquimod and resiquimod as novel immunomodulators

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 6, 2001, Pages 751-755

  Dockrell, D H ^a,b   Kinghorn, G R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; IMIDAZOLE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; RESIQUIMOD;

ANIMAL; CHEMISTRY; HUMAN; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMAL; BIOLOGICAL RESPONSE MODIFIERS; HUMAN; IMIDAZOLES;

EID: 0035654396     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.6.751     Document Type: Review

References (32)

1. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K. et al. (1998). Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339, 1485-92.
2. Chakrabarti, S., Pillay, D., Ratcliffe, D., Cane, P. A., Collingham, K. E. & Milligan, D. W. (2000). Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. Journal of Infectious Diseases 181, 2055-8.
3. Perry, C. M. & Lamb, H. M. (1999). Topical imiquimod. A review of its use in genital warts. Drugs 58, 375-90.
4. Gibson, S. J., Imbertson, L. M., Wagner, T. L., Testerman, T. L., Reiter, M. J., Miller, R. L. et al. (1995). Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. Journal of Inteferon and Cytokine Research 15, 537-45.
5. Wagner, T. L., Norton, V. L., Carlson, G. L., Myhre, P. E., Gibson, S. J., Imbertson, L. M. et al. (1997). Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9, 837-45.
6. Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J. et al. (1995). Cytokine induction by the immunomodulators imiquimod and S-27609. Journal of Leukocyte Biology 58, 365-72.
7. Sick, C., Schultz, U., Münster, U., Meier, J., Kaspers, B. & Staeheli, P. (1998). Promoter structures and differential responses to viral and nonviral inducers of chicken type 1 interferon genes. Journal of Biological Chemistry 273, 9749-54.
8. Tyring, S. K., Arany, I., Stanley, M. A., Tomai, M. A., Miller, R. L., Smith, M. H. et al. (1998). A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. Journal of Infectious Diseases 178, 551-5.
9. Imbertson, L. M., Beaurline, J. M., Couture, A. M., Gibson, S. J., Smith, R. M., Miller, R. L. et al. (1998). Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. Journal of Investigative Dermatology 110, 734-9.
10. Fujisawa, H., Shivji, G. M., Kondo, S., Wang, B., Tomai, M. A., Miller, R. L. et al. (1996). Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. Journal of Interferon and Cytokine Research 16, 555-9.
11. Megyeri, K., Au, W. C., Rosztoczy, I., Raj, N. B., Miller, R. L., Tomai, M. A. et al. (1995). Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Molecular and Cellular Biology 15, 2207-18.
12. Bottrel, R. L. A., Yang, Y.-L., Levy, D. E., Tomai, M. & Reis, L. F. L. (1999). The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6. Antimicrobial Agents and Chemotherapy 43, 856-61.
13. Arany, I., Tyring, S. K., Brysk, M. M., Stanley, M. A., Tomai, M. A., Smith, M. H. et al. (2000). Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. Antimicrobial Agents and Chemotherapy 44, 1869-73.
14. Burns, R. P., Ferbel, B., Tomai, M., Miller, M. & Gaspari, A. A. (2000). The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans'cells. Clinical Immunology 94, 13-23.
15. Suzuki, H., Wang, B., Shivji, G. M., Toto, P., Amerio, P., Tomai, M. A. et al. (2000). Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. Journal of Investigative Dermatology 114, 135-41.
16. Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M. et al. (1999). Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cellular Immunology 191, 10-9.
17. Tomai, M. A., Imbertson, L. M., Stanczak, T. L., Tygrett, L. T. & Waldschmidt, T. J. (2000). The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cellular Immunology 203, 55-65.
18. Hengge, U. R., Goos, M. & Arndt, R. (2000). Topical treatment of warts and mollusca with imiquimod. Annals of Internal Medicine 132, 95.
19. Harrison, C. J., Miller, R. L. & Bernstein, D. I. (1994). Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrobial Agents and Chemotherapy 38, 2059-64.
20. Tomai, M. A., Gibson, S. J., Imbertson, L. M., Miller, R. L., Myhre, P. E., Reiter, M. J. et al. (1995). Immunomodulating and antiviral activities of the imidazoquinoline S-28462. Antiviral Research 28, 253-64.
21. Graul, A. & Castarier, J. (1999). S-28463. Drugs of the Future 24, 622-7.
22. Beutner, K. R., Tyring, S. K., Trofatter, K. F., Douglas, J. M., Spruance, S., Owens, M. L. et al. (1998). Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrobial Agents and Chemotherapy 42, 789-94.
23. Edwards, L., Ferenczy, A., Eron, L., Baker, D., Owens, M. L., Fox, T. L. et al. (1998). Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Archives of Dermatology 134, 25-30.
24. Beutner, K. R., Spruance, S. L., Hougham, A. J., Fox, T. L., Owens, M. L. & Douglas, J. M. (1998). Treatment of genital warts with an immune-response modifier. Journal of the American Academy of Dermatology 38, 230-9.
25. Maitland, J. E. & Maw, R. (2000). An audit of patients who have received imiquimod cream 5% for the treatment of anogenital warts. International Journal of STD & AIDS 11, 268-70.
26. Gilson, R. J. C., Shupack, J. L., Friedman-Kien, A. E., Conant, M. A., Weber, J. N., Nayagam, A. T. et al. (1999). A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. AIDS 13, 2397-404.
27. Syed, T. A., Goswami, J., Ahmadpour, O. A. & Ahmad, S. A. (1998). Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. Journal of Dermatology 25, 309-13.
28. Spruance, S. L., Tyring, S. K., Smith, M. H. & Meng, T.-C. (2000). Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. Journal of Infectious Diseases 184, 196-200.
29. Goldstein, D., Hertzog, P., Tomkinson, E., Couldwell, D., McCarville, S., Parrish, S. et al. (1998). Admininstration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. Journal of Infectious Diseases 178, 858-61.
30. Buates, S. & Matlashewski, G. (1999). Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Diseases 179, 1485-94.
31. Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkel, A. & Owens, M. L. (1999). Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology 41, 1002-7.
32. Vasilakos, J. P., Smith, R. M. A., Gibson, S. J., Lindh, J. M., Pederson, L. K., Reiter, M. J. et al. (2000). Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cellular Immunology 204, 64-74.